In January, NANETS extended its thanks and gratitude to our outgoing executive director. This month, I share the news that NANETS has established a new office headquarters and staff.

It's been a productive month as leaders and committee chairs work to align new staff with the goals identified in our strategic plan. In making this transition, the Board of Directors has added capacity and created a foundation that will support growth and continue to advance our mission to improve neuroendocrine tumor (NET) disease management through increased research and educational opportunities.

The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled.

On January 12, that the New England Journal of Medicine published the results of the NETTER-1 Phase III study evaluating efficacy and safety of Lutathera® (lutetium-177 dotatate), an investigational drug, in patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors (“NETs”).